Molecular pathology for classification of tumors and for efficacy prediction of qualified therapies is usually a quickly increasing area. g., PARP inhibitor) like a consequence of knowledge on the use of PARP inhibitors in BRCA1/2 mutation carriers with State-of-the-art breast most cancers (LoE 1b/GR B/AGO+) [six] (see also the https://samirj318ckr5.blognody.com/profile